News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Vox Royalty (NASDAQ:VOXR) announced its quarterly earnings, reporting $0.12 EPS, which surpassed the consensus estimate of $0.04 by $0.08. The company demonstrated strong financial performance with an 8.16% return on equity and a 190.73% net margin. Despite a slight dip in stock price during …
Sharemaestro market context Price below Trend Line 52 weeks +55.3%Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Why Zealand Pharma stock is in focus after the Royalty Pharma deal Zealand Pharma (CPSE:ZEAL) has drawn fresh attention after agreeing to a US$100 million royalty purchase …
Royalty Pharma plc (RPRX) has filed a Form 144 notice indicating a proposed sale of up to 11,925,082 Class A ordinary shares through J.P. Morgan Securities LLC on NASDAQ. These shares were acquired through various means, including a significant block from a Conversion of …
Vox Royalty Corp. (VOXR) has filed a Form 6-K report to incorporate its Q2 2026 financial exhibits into its existing U.S. registration statements (Form F-10 and Form S-8). This filing includes unaudited interim financial statements for the three and six months ended June 30, …
Vox Royalty Corp. announced strong Q2 2026 operating and financial results, including record net income of $17.0 million and a record cash position of $31.1 million. The company also reiterated its 2026 guidance for royalty and net precious metal receipts and declared a quarterly …
Vox Royalty (VOXR) reported strong Q2 2026 results with net income of $17.0 million, a significant increase from a loss in the prior year, primarily due to an $11.0 million revaluation gain on its offtake-streaming portfolio. The company also announced two opportunistic asset divestments …
Royalty Pharma plc NEW YORK, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced an agreement for $100 million in funding to Zealand Pharma in exchange for Zealand Pharma's economics related to rusfertide (PTG-300), a potential first-in-class therapy for polycythemia …
Zealand Pharma Company announcement – No. 38 / 2026 Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide Zealand Pharma will receive USD 100 million for the sale of its economic …
Hyster-Yale (NYSE: HY) has declared a regular cash dividend of $0.365 per share for both Class A and Class B common stock. This dividend will be paid on September 15, 2026, to shareholders who are on record as of September 1, 2026. The company, …
This article provides a precision trading analysis for Royal Gold Inc. (RGLD), highlighting strong sentiment across all horizons supporting an overweight bias. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also …
Hyster-Yale, Inc. announced that its Board of Directors has declared a regular cash dividend of 36.5 cents per share. This dividend is payable on both Class A and Class B Common Stock and will be distributed on September 15, 2026, to stockholders of record …
Search by ticker symbol or company name and select a result to open its chart.